Pexidartinib (PLX3397), JNJ-40346527, and PLX7486 are tyrosine kinase inhibitors of CSF-1R signaling that are currently being used in phase I–III clinical trials for different types of cancers [155,156,157,158]. The gene discussed is CSF1R; the disease is cancer.